Construction and Feasibility Study of a Home-Based Intelligent Symptom Management Program for Lung Cancer Patients Receiving Combined Drug Therapy Based on Symptom Journey Profiling
2 juni 2026 bijgewerkt door: Feifei Huang
The goal of this clinical trial is to develop and evaluate a home-based intelligent symptom management program based on symptom journey profiles for patients with lung cancer receiving combination drug therapy. The program will be delivered through the "Zhihu Feifang" WeChat mini-program and is designed to help patients monitor symptoms, receive personalized symptom management recommendations, and obtain timely support during treatment intervals at home.
The study will assess the feasibility, acceptability, and preliminary effectiveness of this intelligent symptom management program.
The main research questions are as follows: (1) Is the intelligent symptom management program feasible and acceptable for patients with lung cancer receiving combination drug therapy? (2) Compared with usual care, can the program reduce symptom burden and improve symptom self-management ability? (3) Can the program improve quality of life and help patients identify and manage symptoms more promptly during treatment intervals? Researchers will compare the intelligent symptom management program with usual care to evaluate its preliminary effectiveness. Participants will be randomly assigned to either the intervention group or the usual care group.
Participants in the intervention group will: (1) Receive usual care plus the "Zhihu Feifang" WeChat mini-program intervention; (2) Use the mini-program during four consecutive treatment intervals, lasting approximately 4 months; (3) Complete regular symptom assessments through the mini-program; (4) Receive personalized symptom management education, coping strategies, and risk alerts based on their symptom severity and symptom changes; (5) Receive nurse monitoring and follow-up support when needed; (6) Complete questionnaires at baseline and at follow-up time points during the study; (7) Some participants may also take part in an interview after the intervention to share their experience and suggestions.
Participants in the usual care group will receive routine follow-up care, including health education, telephone follow-up, and medical visit guidance.
Studie Overzicht
Toestand
Nog niet aan het werven
Studietype
Ingrijpend
Inschrijving (Geschat)
60
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Feifei Huang Huang
- Telefoonnummer: +86 13763869099
- E-mail: pt860315@163.com
Studie Contact Back-up
- Naam: Chenxing Zhang
- Telefoonnummer: +86 18150815135
- E-mail: zcxing2024@163.com
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Diagnosed with primary lung cancer confirmed by histology or cytology
- First-time recipient of combination drug therapy, with an expected treatment course of at least 4 cycles; the combination regimen is not restricted
- Aged 18 years or older
- Able to use a smartphone
- Eastern Cooperative Oncology Group performance status score of 2 or lower
- Aware of their own diagnosis and medication regimen
- Voluntarily agree to participate in this study
Exclusion Criteria:
- History of mental illness or currently receiving mental health treatment
- Diagnosis of malignancy in another organ site
- Presence of cognitive impairment, indicated by 3 or more errors on the Short Portable Mental Status Questionnaire
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Interventie groep
|
The intervention group will receive routine care plus the home-based intelligent symptom management program.
Participants will: ① complete regular symptom assessments through the mini-program; ② receive individualized symptom journey profiles based on symptom severity, symptom changes, and supportive care needs; ③ receive personalized health education, symptom management strategies, coping recommendations, and risk alerts; ④ receive nurse monitoring through the healthcare provider interface; ⑤ receive timely follow-up support when symptoms worsen or when additional guidance is needed; and ⑥ some participants may take part in interviews after the intervention to share their experience, satisfaction, and suggestions.
|
|
Actieve vergelijker: Controlegroep
|
① Health education: prior to treatment, research nurses will provide patients with a "Home Health Education Manual for Patients with Lung Cancer," covering management of common adverse reactions, medication safety, dietary guidance, and exercise recommendations; ② Telephone follow-up: routine follow-up phone calls will be conducted according to departmental practice to assess symptom changes, psychological status, and medication adherence, while providing verbal guidance and health education; ③ Medical visit guidance: if patients report worsening symptoms or new discomfort, nurses will provide guidance or recommend timely outpatient review or hospitalization assessment in the oncology department.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in symptom burden measured by the Symptom Assessment Scale for Intervals of Combination Therapy in Patients with Lung Cancer
Tijdsspanne: Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
Symptom burden will be assessed using the Symptom Assessment Scale for Intervals of Combination Therapy in Patients with Lung Cancer.
The scale assesses symptom severity over the previous 24 hours and includes seven symptom systems: respiratory and circulatory symptoms, gastrointestinal symptoms, neuromuscular symptoms, dermatological symptoms, sleep-related symptoms, general somatic symptoms, and psychological symptoms.
The scale consists of 60 symptom items, each rated on an 11-point numeric rating scale ranging from 0 (no symptom) to 10 (most severe symptom).
Total scores range from 0 to 600, with higher scores indicating greater symptom burden and worse symptom severity.
|
Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in quality of life measured by the Functional Assessment of Cancer Therapy-Lung, version 4.0 (FACT-L, V4.0)
Tijdsspanne: Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Lung, version 4.0.
The scale consists of 36 items across five domains: physical well-being, social/family well-being, emotional well-being, functional well-being, and lung cancer-specific concerns.
Items are rated on a 5-point Likert scale ranging from 0 ("not at all") to 4 ("very much").
Negatively worded items are reverse scored as appropriate.
Total scores range from 0 to 144, with higher scores indicating better quality of life.
|
Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
|
Change in self-management behavior measured by the Self-Management Behavior Scale for Lung Cancer Survivors
Tijdsspanne: Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
Self-management behavior will be assessed using the Self-Management Behavior Scale for Lung Cancer Survivors.
The scale includes 47 items across six domains: daily life management, symptom management, follow-up management, information and resource management, emotional management, and hope management.
Items are rated on a 5-point Likert scale ranging from 1 ("completely unable to do") to 5 ("always able to do").
Total scores range from 47 to 235, with higher scores indicating better self-management behavior among lung cancer survivors.
|
Baseline, at the end of Cycle 2 (each cycle is 21 days), and at the end of Cycle 4 (each cycle is 21 days).
|
|
Mini-program usability measured by the Chinese version of the mHealth App Usability Questionnaire (MAUQ)
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days).
|
Mini-program usability will be assessed using the Chinese version of the mHealth App Usability Questionnaire (MAUQ).
The questionnaire consists of 21 items across three domains: ease of use and satisfaction (8 items), system information arrangement (6 items), and usefulness (7 items).
Items are rated on a 7-point Likert scale ranging from 1 ("strongly agree") to 7 ("strongly disagree").
Mean scores closer to 1 indicate higher usability of the mHealth mini-program.
|
At the end of Cycle 4 (each cycle is 21 days).
|
|
Recruitment rate
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days).
|
The number of patients who agree to participate in the study divided by the number of patients with lung cancer who meet the eligibility criteria.
|
At the end of Cycle 4 (each cycle is 21 days).
|
|
Retention rate
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days).
|
The number of patients with lung cancer who complete the study procedures divided by the number of patients enrolled in the study.
Reasons for withdrawal will also be recorded.
|
At the end of Cycle 4 (each cycle is 21 days).
|
|
Attrition rate
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days).
|
The number of patients with lung cancer who withdraw from the intervention or fail to complete all assessments during the study divided by the number of patients enrolled in the study.
Reasons for attrition will also be recorded.
|
At the end of Cycle 4 (each cycle is 21 days).
|
|
Satisfaction with the intervention program and the mini-program
Tijdsspanne: At the end of Cycle 4 (each cycle is 21 days).
|
A qualitative interview was used to assess the participants' satisfaction with the intervention program and the mini-program.
|
At the end of Cycle 4 (each cycle is 21 days).
|
|
Adverse event
Tijdsspanne: From Cycle 1 to Cycle 4 (each cycle is 21 days）
|
Adverse events will be recorded using a self-developed adverse event registration form, including negative emotional reactions during the intervention process (e.g., fear, silence, emotional indifference), causes of adverse events, management measures, and follow-up outcomes.
|
From Cycle 1 to Cycle 4 (each cycle is 21 days）
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Feifei Huang, Fujian Medical University
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
25 mei 2026
Primaire voltooiing (Geschat)
30 juni 2027
Studie voltooiing (Geschat)
30 juni 2027
Studieregistratiedata
Eerst ingediend
21 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
2 juni 2026
Eerst geplaatst (Werkelijk)
8 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
2 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FJMU-IRB-2025-442
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
The datasets are not publicly available due privacy reasons but are available from the director under reasonable request.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .